Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

DSGN

Design Therapeutics Inc

Apr 21 • 12:22PM ET

13.21

+0.05 0.42 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE REGN VRTX MRNA BNTX CRSP EDIT NTLA SGMO BEAM

| Held by: VTI IWM VXF IBB IWN SCHA FESM DWAS VTWO DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.22	Insider Own	44.44%	Shs Outstand	60.40M	Perf Week	4.55%
Market Cap	814.99M	Forward P/E	-	EPS next Y	-1.64	Insider Trans	0.00%	Shs Float	34.26M	Perf Month	28.17%
Enterprise Value	596.68M	PEG	-	EPS next Q	-0.32	Inst Own	47.85%	Short Float	6.07%	Perf Quarter	39.84%
Income	-69.79M	P/S	-	EPS this Y	-11.75%	Inst Trans	3.64%	Short Ratio	7.41	Perf Half Y	130.22%
Sales	0.00M	P/B	3.76	EPS next Y	-20.42%	ROA	-29.15%	Short Interest	2.08M	Perf YTD	40.88%
Book/sh	3.52	P/C	3.71	EPS next 5Y	-18.11%	ROE	-30.70%	52W High	13.50 -2.11%	Perf Year	268.10%
Cash/sh	3.56	P/FCF	-	EPS past 3/5Y	-2.32% -52.23%	ROIC	-32.74%	52W Low	3.11 325.60%	Perf 3Y	116.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.28% 5.19%	Perf 5Y	-32.41%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-39.08%	Oper. Margin	-	ATR (14)	0.65	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.14	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	70.03	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	17.14	EPS Q/Q	-13.12%	SMA20	11.36%	Beta	1.72	Target Price	14.67
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	20.94%	Rel Volume	1.66	Prev Close	13.16
Employees	124	LT Debt/Eq	0.00	Earnings	Mar 09 AMC	SMA200	64.98%	Avg Volume	280.69K	Price	13.21
IPO	Mar 26, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	23.73% -	Trades		Volume	218,545	Change	0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-16-26	Initiated	Jefferies	Buy	$15
Jan-07-26	Initiated	Oppenheimer	Outperform	$18
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform	$14
Dec-03-25	Initiated	Craig Hallum	Buy	$15
Nov-20-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$13
May-07-24	Upgrade	Piper Sandler	Neutral → Overweight	$6 → $12
Nov-14-23	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $6
Aug-15-23	Downgrade	Wedbush	Outperform → Neutral	$19 → $6
Aug-15-23	Downgrade	SVB Securities	Outperform → Market Perform	$6
Aug-15-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$23 → $7
May-04-23	Upgrade	Goldman	Sell → Neutral	$6
Jun-10-22	Initiated	Wedbush	Outperform	$21
May-02-22	Initiated	RBC Capital Mkts	Outperform	$30
Jan-19-22	Initiated	Goldman	Sell	$10
Apr-20-21	Initiated	SVB Leerink	Outperform	$36
Apr-20-21	Initiated	Piper Sandler	Overweight	$42
Apr-20-21	Initiated	Goldman	Neutral	$28

Show Previous Ratings

Mar-09-26 04:01PM	Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Feb-26-26 05:53AM	Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference (MarketBeat)
Feb-18-26 08:00AM	Design Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-26-25 08:00AM	Design Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-20-25 09:21AM	Here Are Thursdays Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More (24/7 Wall St.) +7.22%
04:01PM	Loading…
Nov-05-25 04:01PM	Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Sep-10-25 04:01PM	Design Therapeutics Appoints Justin Gover to Board of Directors (GlobeNewswire) -7.68%
Aug-27-25 08:00AM	Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-07-25 04:01PM	Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Second Quarter 2025 Financial Results (GlobeNewswire) -8.74% +7.81%
Jun-04-25 07:00AM	Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 (GlobeNewswire)
May-28-25 08:00AM	Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-25 08:00AM	Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference (GlobeNewswire)
May-07-25 04:01PM	Design Therapeutics Highlights Momentum Across Lead GeneTAC Programs and Reports First Quarter 2025 Financial Results (GlobeNewswire) -8.26% +5.71%
May-02-25 07:58AM	Design Therapeutics reports positive outcomes from trial of DT-168 eye drops (Clinical Trials Arena)
May-01-25 08:00AM	Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy (GlobeNewswire)
04:01PM	Loading…
Apr-21-25 04:01PM	Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 (GlobeNewswire) +10.31%
Apr-17-25 08:00AM	Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer (GlobeNewswire)
07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire)
Mar-12-25 12:00PM	Design Therapeutics (DSGN) Upgraded to Buy: Here's Why (Zacks) -6.94%
Mar-10-25 07:07AM	Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 08:00AM	Design Therapeutics to Participate in Leerink's Global Healthcare Conference (GlobeNewswire) -7.00%
Nov-13-24 08:00AM	Design Therapeutics to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire) +8.54%
Nov-07-24 04:01PM	Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio (GlobeNewswire)
Sep-10-24 08:00AM	Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire) +15.69%
Aug-21-24 09:55AM	Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet (Zacks)
Aug-05-24 08:00AM	Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC Portfolio (GlobeNewswire)
May-22-24 08:50PM	The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains (InvestorPlace)
May-10-24 03:36PM	Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review (GuruFocus.com)
May-08-24 11:55PM	DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones (GlobeNewswire)
07:12AM	Loading…
May-07-24 07:12AM	--Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral (MT Newswires) +28.49%
06:30AM	Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
Mar-20-24 10:31AM	Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.97%
06:58AM	Q4 2023 Design Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:53PM	DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress (GuruFocus.com)
04:01PM	Design Therapeutics Outlines Progress Across GeneTAC Platform and Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-12-24 06:30AM	Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update (GlobeNewswire)
Dec-18-23 12:00PM	Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-14-23 07:28PM	Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update (GuruFocus.com) +11.71%
Nov-13-23 04:05PM	Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024 (GlobeNewswire)
Aug-15-23 03:02PM	Why Shares of Design Therapeutics Are Plummeting on Tuesday (Motley Fool) -70.46%
09:59AM	Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls (The Fly)
02:34AM	4 big analyst cuts: Urban Outfitters has 'limited' EPS upside, per Citi (Investing.com)
Aug-14-23 04:05PM	Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
04:01PM	Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia (GlobeNewswire)
Jun-18-23 08:03AM	Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock \ (Simply Wall St.)
May-31-23 06:30AM	Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire) -6.01%
May-09-23 04:05PM	Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results (GlobeNewswire) -11.66%
May-08-23 06:05AM	We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely (Simply Wall St.)
Apr-24-23 06:30AM	Design Therapeutics to Present Preclinical Data on its GeneTAC Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023 (GlobeNewswire)
Apr-11-23 09:55AM	Why Design Therapeutics (DSGN) Stock Is Going Nowhere But Down (InvestorPlace)
Apr-04-23 02:47PM	Down More Than 60%: Analysts Say Buy These 3 Beaten-Down Stocks Before They Rebound (TipRanks) -7.32%
Mar-14-23 04:05PM	Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research)
Feb-08-23 06:30AM	Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference (GlobeNewswire) -8.79%
Dec-21-22 06:46AM	Daily Vickers Top Buyers & Sellers for 12/21/2022 (Argus Research) +5.33%
Dec-14-22 05:15AM	Independent Director Rodney Lappe Just Bought 15% More Shares In Design Therapeutics, Inc. (NASDAQ:DSGN) (Simply Wall St.)
Dec-07-22 04:01PM	Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress (GlobeNewswire) -6.00% -33.33%
Nov-28-22 10:37AM	Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth (Simply Wall St.)
Nov-03-22 04:05PM	Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-17-22 04:05PM	Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022 (GlobeNewswire)
Sep-22-22 06:30AM	Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
Aug-08-22 04:05PM	Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-03-22 06:30AM	Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference (GlobeNewswire) +6.33%
Jun-21-22 09:57AM	Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth (Simply Wall St.) +6.24%
Jun-01-22 06:30AM	Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-09-22 04:05PM	Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results (GlobeNewswire)
Mar-30-22 06:30AM	Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC Molecule for the Treatment of Friedreich Ataxia (GlobeNewswire)
Mar-23-22 02:53PM	Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months (Simply Wall St.)
Mar-10-22 04:02PM	Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-09-22 06:30AM	Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022 (GlobeNewswire) +9.41%
Feb-28-22 04:05PM	Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC Molecule for Friedreich Ataxia (GlobeNewswire)
Feb-10-22 06:30AM	Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference (GlobeNewswire) +7.02%
Feb-01-22 04:05PM	Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer (GlobeNewswire)
Jan-19-22 12:51PM	Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating (Benzinga) -5.86%
Dec-23-21 05:00AM	Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) +5.09%
Nov-09-21 04:05PM	Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results (GlobeNewswire)
Sep-24-21 07:55AM	Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months (Simply Wall St.)
Sep-08-21 06:30AM	Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1 (GlobeNewswire)
Sep-03-21 07:33AM	4 Stocks Insiders Are Buying (Benzinga)
Aug-09-21 04:05PM	Design Therapeutics Reports GeneTAC Portfolio Progress and Second Quarter 2021 Results (GlobeNewswire) +6.19%
Jun-26-21 04:30AM	We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely (Simply Wall St.)
Jun-07-21 04:10PM	Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Design Therapeutics Expands Board of Directors with Key Appointments (GlobeNewswire)
May-10-21 04:05PM	Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results (GlobeNewswire) -6.82%
Mar-30-21 04:05PM	Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -13.20%
Mar-25-21 11:56PM	Design Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Logos Global Master Fund LP	Director	Nov 18 '25	Proposed Sale	7.43	120,000	891,600		Nov 18 04:28 PM
Logos Global Master Fund LP	Director	Nov 14 '25	Proposed Sale	7.06	620,000	4,377,200		Nov 14 04:18 PM
Logos Global Master Fund LP	Director	Nov 07 '25	Proposed Sale	6.87	415,000	2,851,050		Nov 07 05:24 PM
William Arsani	Director	Aug 13 '25	Sale	5.25	562,627	2,953,792	1,000,000	Aug 14 04:15 PM
Logos Opportunities Fund II LP	Director	Aug 13 '25	Proposed Sale	4.98	217,627	1,083,783		Aug 13 08:05 PM
Logos Global Master Fund LP	Director	Aug 13 '25	Proposed Sale	4.98	345,000	1,718,100		Aug 13 08:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DSGN

Design Therapeutics Inc

Upgrade your Finviz experience